Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sarepta Therapeutics

19.37
+0.34001.79%
Post-market: 19.440.0686+0.35%19:59 EDT
Volume:4.01M
Turnover:77.55M
Market Cap:1.90B
PE:-7.48
High:19.74
Open:18.98
Low:18.90
Close:19.03
Loading ...

Cautious Hold Rating on Sarepta Therapeutics Amid Limited LGMD Market and ELEVIDYS Uncertainties

TIPRANKS
·
16 Apr

Sarepta Therapeutics Inc: U.S. FDA Has Confirmed That Screening and Dosing May Proceed in Study Srp-9005-101 for Lgmd2c/R5

THOMSON REUTERS
·
15 Apr

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

THOMSON REUTERS
·
15 Apr

Sarepta Therapeutics Inc: Data Expected for Srp-9003 for Lgmd2e/R4 by Mid-2025

THOMSON REUTERS
·
15 Apr

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

Business Wire
·
15 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Wells Fargo, American Express, Mondelez

Reuters
·
12 Apr

Sarepta Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
11 Apr

BUZZ-Sarepta rises after Wells Fargo starts coverage with 'overweight' rating

Reuters
·
11 Apr

Sarepta Therapeutics (SRPT) Receives a Buy from Morgan Stanley

TIPRANKS
·
11 Apr

Sarepta price target lowered to $112 from $150 at Guggenheim

TIPRANKS
·
10 Apr

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

Zacks
·
10 Apr

Top Stock Reports for Walmart, Coca-Cola & HSBC

Zacks
·
09 Apr

Oppenheimer Adjusts Price Target on Sarepta Therapeutics to $184 From $215, Keeps Outperform Rating

MT Newswires Live
·
07 Apr

Sarepta Therapeutics (SRPT) Receives a Hold from Scotiabank

TIPRANKS
·
07 Apr

Sarepta Therapeutics (SRPT) Gets a Hold from RBC Capital

TIPRANKS
·
05 Apr

Sarepta Says EU Regulators Temporarily Halt Enrollment, Dosing in Elevidys Trials

MT Newswires Live
·
04 Apr

Sarepta price target lowered to $183 from $202 at Needham

TipRanks
·
04 Apr

Sarepta announces EU regulators temporarily halted dosing of ELEVIDYS

TIPRANKS
·
04 Apr

Sarepta halts three studies testing gene therapy for muscle disorder

Reuters
·
04 Apr

Sarepta Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Apr